BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011) NSQ NSCLC: Baseline Demographics / Characteristics BioAtla study enrolled a heavily pretreated 3L+ population Age, y, mean (SD) Number of prior systemic therapies, n (%) 1 2 3 >4 Received prior anti-PD-1/L1 treatment, n (%) Yes No EGFR mutation status, n (%) Wild-type Mutant Unknown or missing bicatla BA3011 monotherapy (N=23) 68.3 (8.0) 4 (17.4) 6 (26.1) 9 (39.1) 4 (17.4) 21 (91.3) 2 (8.7) 16 (69.6) 4 (17.4) 3 (13.0) Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. Data Cut Date: 30Jun23 BA3011 + nivolumab (N=17) 68.9 (8.2) 2 (11.8) 3 (17.6) 2 (11.8) 10 (58.8) 15 (88.2) 2 (11.8) 13 (76.5) 2 (11.8) 2 (11.8) Total (N=40) 68.6 (8.0) 6 (15.0) 9 (22.5) 11 (27.5) 14 (35.0) 36 (90.0) 4 (10.0) 27 (67.5) 6 (15.0) 7 (17.5) BioAtla| Overview 32

View entire presentation